Age
Item
age greater than or equal to 18 years
boolean
C0001779 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma | Squamous cell carcinoma | Adenocarcinoma | Carcinoma, Large Cell
Item
histologically confirmed nsclc (squamous cell carcinoma, adenocarcinoma, large cell carcinoma).
boolean
C0007131 (UMLS CUI [1])
C0007137 (UMLS CUI [2])
C0001418 (UMLS CUI [3])
C0206704 (UMLS CUI [4])
Non-Small Cell Lung Carcinoma unresectable | TNM clinical staging | Pleural effusion
Item
unresectable stage iiib with pleural effusion or stage iv nsclc
boolean
C0007131 (UMLS CUI [1,1])
C1519810 (UMLS CUI [1,2])
C3258246 (UMLS CUI [2])
C0032227 (UMLS CUI [3])
ECOG performance status
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Intravenous bisphosphonates | pamidronate | zoledronic acid
Item
patients who received an iv bisphosphonate (e.g.pamidronate; zoledronic acid)
boolean
C1955566 (UMLS CUI [1])
C0043603 (UMLS CUI [2])
C0257685 (UMLS CUI [3])
Diphosphonates Oral | Alendronate | Etidronate | Risedronate | Tiludronate | Ibandronate
Item
patients who received an oral bisphosphonate therapy in the 6 months prior to screening (alendronate; etidronate; risedronate; tiludronate; ibandronate)
boolean
C0012544 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0102118 (UMLS CUI [2])
C0086268 (UMLS CUI [3])
C0246719 (UMLS CUI [4])
C0145942 (UMLS CUI [5])
C0379199 (UMLS CUI [6])
Investigational New Drugs Associated with Toxic nephropathy | Investigational New Drugs Related Kidney Excretion
Item
patients who are currently receiving any investigational drugs that are suspected to have renal toxicity and/or are excreted by the kidneys
boolean
C0013230 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0595916 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C0439849 (UMLS CUI [2,2])
C0022646 (UMLS CUI [2,3])
C0221102 (UMLS CUI [2,4])
Hypersensitivity Clinical Significance zoledronic acid | Hypersensitivity Clinical Significance Diphosphonates | Hypersensitivity Clinical Significance zoledronic acid Excipient | Hypersensitivity Clinical Significance Mannitol | Hypersensitivity Clinical Significance sodium citrate
Item
known clinically significant hypersensitivity to zoledronic acid or other bisphosphonates or any of the excipients in the formulation of zoledronic acid (mannitol, sodium citrate)
boolean
C0020517 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0257685 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C2826293 (UMLS CUI [2,2])
C0012544 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C2826293 (UMLS CUI [3,2])
C0257685 (UMLS CUI [3,3])
C0015237 (UMLS CUI [3,4])
C0020517 (UMLS CUI [4,1])
C2826293 (UMLS CUI [4,2])
C0024730 (UMLS CUI [4,3])
C0020517 (UMLS CUI [5,1])
C2826293 (UMLS CUI [5,2])
C0142825 (UMLS CUI [5,3])
Abnormal renal function | Creatinine clearance Abnormal
Item
abnormal renal function or creatinine clearance
boolean
C0151746 (UMLS CUI [1])
C0812399 (UMLS CUI [2,1])
C0205161 (UMLS CUI [2,2])
Metastatic malignant neoplasm to brain Unstable
Item
unstable brain metastasis
boolean
C0220650 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
Childbearing Potential Contraceptive methods Inadequate | Breast Feeding
Item
women of childbearing potential not using a medically recognized form of contraception, as well as women who are breastfeeding
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
C0006147 (UMLS CUI [2])
Condition Non-Malignant Affecting Evaluation Primary Endpoint | Condition Non-Malignant Affecting Therapeutic procedure | Condition Non-Malignant Preventing Protocol Compliance
Item
patients with nonmalignant conditions which would confound the evaluation of the primary endpoint, impair tolerance of therapy, or prevent compliance to the protocol
boolean
C0348080 (UMLS CUI [1,1])
C1518371 (UMLS CUI [1,2])
C0392760 (UMLS CUI [1,3])
C1261322 (UMLS CUI [1,4])
C2986535 (UMLS CUI [1,5])
C0348080 (UMLS CUI [2,1])
C1518371 (UMLS CUI [2,2])
C0392760 (UMLS CUI [2,3])
C0087111 (UMLS CUI [2,4])
C0348080 (UMLS CUI [3,1])
C1518371 (UMLS CUI [3,2])
C1292733 (UMLS CUI [3,3])
C0525058 (UMLS CUI [3,4])